Shire Persists With Drug for Premature Babies After Study Fails
This article is for subscribers only.
Shire Plc plans to keep developing an experimental treatment for premature babies even after the therapy failed to meet the main goal of a mid-stage study.
The treatment, known as SHP-607, didn’t help reduce the severity of a blindness-causing condition in a study of 121 infants born at least 12 weeks prematurely, Shire said Thursday in a statement. The therapy did show promise in alleviating lung and brain ailments that affect the infants’ development, and the Dublin-based drugmaker said it will discuss late-stage research plans with regulators later this year.